Alkermes Plc
NASDAQ:ALKS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
23.01
32.56
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ALKS stock under the Base Case scenario is 28.4 USD. Compared to the current market price of 29.16 USD, Alkermes Plc is Overvalued by 3%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Alkermes Plc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ALKS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Alkermes Plc
Balance Sheet Decomposition
Alkermes Plc
Current Assets | 1.6B |
Cash & Short-Term Investments | 908.9m |
Receivables | 370.2m |
Other Current Assets | 285.1m |
Non-Current Assets | 591.1m |
Long-Term Investments | 18.9m |
PP&E | 311.5m |
Intangibles | 83.9m |
Other Non-Current Assets | 176.8m |
Current Liabilities | 453.7m |
Accounts Payable | 37m |
Accrued Liabilities | 411.3m |
Other Current Liabilities | 5.3m |
Non-Current Liabilities | 409.5m |
Long-Term Debt | 285.8m |
Other Non-Current Liabilities | 123.7m |
Earnings Waterfall
Alkermes Plc
Revenue
|
1.5B
USD
|
Cost of Revenue
|
-253.3m
USD
|
Gross Profit
|
1.3B
USD
|
Operating Expenses
|
-815.3m
USD
|
Operating Income
|
436.5m
USD
|
Other Expenses
|
-103.2m
USD
|
Net Income
|
333.3m
USD
|
Free Cash Flow Analysis
Alkermes Plc
USD | |
Free Cash Flow | USD |
ALKS Profitability Score
Profitability Due Diligence
Alkermes Plc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Alkermes Plc's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
ALKS Solvency Score
Solvency Due Diligence
Alkermes Plc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Alkermes Plc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALKS Price Targets Summary
Alkermes Plc
According to Wall Street analysts, the average 1-year price target for ALKS is 35.62 USD with a low forecast of 21.21 USD and a high forecast of 52.5 USD.
Dividends
Current shareholder yield for ALKS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ALKS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alkermes Plc is a global biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 2,211 full-time employees. The firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The company has a portfolio of commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. The firm's products include ALKERMES, ARISTADA, ARISTADA INITIO, LinkeRx, LYBALVI, NanoCrystal and VIVITROL. Its other trademark includes INVEGA SUSTENNA, INVEGA TRINZA, TREVICTA, XEPLION, and RISPERDAL CONSTA, KEYTRUDA and VUMERITY. The firm's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
Contact
IPO
Employees
Officers
The intrinsic value of one ALKS stock under the Base Case scenario is 28.4 USD.
Compared to the current market price of 29.16 USD, Alkermes Plc is Overvalued by 3%.